Lv2
178 积分 2024-09-11 加入
Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders
13天前
已完结
Fremanezumab: Pediatric First Approval
14天前
已完结
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial
15天前
已完结
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial
15天前
已完结
Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial
15天前
已完结
Interictal Burden of Migraine: A Narrative Review
21天前
已完结
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
24天前
已完结
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
27天前
已完结
Early treatment in migraine - A call to shift prevention from attacks to disease progression: A position statement from the International Headache Society
29天前
已完结
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study
1个月前
已完结
皖公网安备34019202002308
